Insulin glargine/Lixisenatide (HOE901/AVE0010)
EFC14113
Phase 3 small_molecule completed
Quick answer
Insulin glargine/Lixisenatide (HOE901/AVE0010) for Type 2 Diabetes Mellitus is a Phase 3 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pasteur
- Indication
- Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed